These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29483037)

  • 1. Treatment with the SQ house dust mite sublingual immunotherapy tablet may be initiated year-round.
    Nolte H; Bernstein DI; Kleine-Tebbe J; Fejerskov PA; Li Q; Lu S; Nelson HS
    J Allergy Clin Immunol Pract; 2018; 6(5):1758-1760.e1. PubMed ID: 29483037
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
    Demoly P; Kleine-Tebbe J; Rehm D
    Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trial.
    Zieglmayer P; Nolte H; Nelson HS; Bernstein DI; Kaur A; Jacobi H; Lemell P; Schmutz R; Zieglmayer R; Horak F
    Ann Allergy Asthma Immunol; 2016 Dec; 117(6):690-696.e1. PubMed ID: 27979028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet.
    Nolte H; Bernstein DI; Sussman GL; Svanholm Fogh B; Lu S; Husøy B; Nelson HS
    J Allergy Clin Immunol Pract; 2018; 6(6):2081-2086.e1. PubMed ID: 29432959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma.
    Mauro M; Boni E; Makri E; Incorvaia C
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1937-43. PubMed ID: 26565665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for house-dust mite allergy.
    Nelson HS
    Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study.
    Okamiya K; Sekino H; Azuma R; Kudo M; Sakaguchi M; Nemoto F; Muramatsu N; Maekawa Y; Tanaka A
    J Asthma; 2019 Dec; 56(12):1347-1355. PubMed ID: 30444150
    [No Abstract]   [Full Text] [Related]  

  • 11. Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
    Ohashi-Doi K; Kito H; Du W; Nakazawa H; Ipsen H; Gudmann P; Lund K
    Int Arch Allergy Immunol; 2017; 174(1):26-34. PubMed ID: 28950271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
    Nolte H; Casale TB; Lockey RF; Fogh BS; Kaur A; Lu S; Nelson HS
    J Allergy Clin Immunol Pract; 2017; 5(1):84-89.e3. PubMed ID: 27838323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy of house dust mite respiratory allergy in China.
    Cheng L; Zhou WC
    Allergol Immunopathol (Madr); 2019; 47(1):85-89. PubMed ID: 29921463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms.
    Gunawardana NC; Zhao Q; Carayannopoulos LN; Tsai K; Malkov VA; Selverian D; Clarke G; Mant T; Butts BD; Lund K; Hansel TT; Nolte H
    J Allergy Clin Immunol; 2018 Feb; 141(2):785-788.e9. PubMed ID: 28911971
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
    Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
    J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual sublingual immunotherapy with Japanese Cedar Pollen droplets and House Dust Mite tablets.
    Matsuoka T; Igarashi S; Kuroda Y; Fukano C; Natsui K; Doi-Ohashi K; Masuyama K
    Allergol Int; 2019 Oct; 68(4):533-535. PubMed ID: 30962053
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
    Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophilic esophagitis after desensitization to dust mites with sublingual immunotherapy.
    Béné J; Ley D; Roboubi R; Gottrand F; Gautier S
    Ann Allergy Asthma Immunol; 2016 Jun; 116(6):583-4. PubMed ID: 27067457
    [No Abstract]   [Full Text] [Related]  

  • 20. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.